Osaka, Japan
Osaka, Japan

Takeda Pharmaceutical Company Ltd is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. Wikipedia.


Time filter

Source Type

Patent
Takeda Pharmaceutical | Date: 2016-11-18

The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.


Patent
Takeda Pharmaceutical | Date: 2017-02-22

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I)


Patent
Takeda Pharmaceutical | Date: 2017-02-01

Provided is a compound having a superior PKC inhibitory action, and useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like, or a salt thereof. A compound represented by the formula (I):


Patent
Takeda Pharmaceutical | Date: 2017-02-15

Provided is a production method of a synthetic intermediate for a heterocyclic compound having a renin inhibitory activity and useful as a prophylactic or therapeutic drug for diabetic nephropathy, hypertension and the like. A production method of a compound represented by the formula (III-1a), the formula (III-1b), the formula (III-1c) and/or the formula (III-1d);


Patent
Takeda Pharmaceutical | Date: 2017-01-25

A solid dispersion for achieving improved solubility and absorbability of a pharmaceutically active ingredient, which contains (1) an amorphous pharmaceutically active ingredient, (2) one or more substances selected from among methyl cellulose and organic acids and (3) an enteric base material. In cases where methyl cellulose is contained therein, the solid dispersion does not contain any water-soluble polymer other than methyl cellulose.


Patent
Takeda Pharmaceutical | Date: 2017-01-18

The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula


Patent
Takeda Pharmaceutical | Date: 2017-01-18

The present invention provides a method of efficiently producing an optically active 6-(3-aminopiperidin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivative. The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.


Patent
Takeda Pharmaceutical | Date: 2017-04-05

The present invention provides a novel technique for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.010^(8) bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be preferably used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.


Patent
Takeda Pharmaceutical | Date: 2017-03-22

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimers disease, schizophrenia, pain, sleep disorder, Parkinsons disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I)_(1-6) alkyl group substituted by 1 to 5 halogen atoms; and X is -CH= or -N=, or a salt thereof.


Patent
Takeda Pharmaceutical | Date: 2017-04-19

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimers disease, schizophrenia, pain, sleep disorder, Parkinsons disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof.

Loading Takeda Pharmaceutical collaborators
Loading Takeda Pharmaceutical collaborators